Pomalidomide is active in the treatment of anemia associated with myelofibrosis Academic Article uri icon

Overview

MeSH Major

  • Anemia
  • Hematinics
  • Primary Myelofibrosis
  • Thalidomide

abstract

  • Pomalidomide therapy at 0.5 or 2 mg/d with or without an abbreviated course of prednisone is well tolerated in patients with myelofibrosis and active in the treatment of anemia.

publication date

  • September 20, 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4979191

Digital Object Identifier (DOI)

  • 10.1200/JCO.2008.21.7356

PubMed ID

  • 19652059

Additional Document Info

start page

  • 4563

end page

  • 9

volume

  • 27

number

  • 27